vs
AXCELIS TECHNOLOGIES INC（ACLS）与Prestige Consumer Healthcare Inc.（PBH）财务数据对比。点击上方公司名可切换其他公司
Prestige Consumer Healthcare Inc.的季度营收约是AXCELIS TECHNOLOGIES INC的1.2倍（$283.4M vs $238.3M），Prestige Consumer Healthcare Inc.净利率更高（16.5% vs 14.4%，领先2.1%），Prestige Consumer Healthcare Inc.同比增速更快（-2.4% vs -5.6%），Prestige Consumer Healthcare Inc.自由现金流更多（$75.3M vs $-8.9M），过去两年Prestige Consumer Healthcare Inc.的营收复合增速更高（1.2% vs -2.8%）
Axcelis Technologies是一家美国半导体设备供应商，1995年成立，总部位于美国马萨诸塞州贝弗利。公司面向全球半导体制造行业，从事半导体生产核心设备的设计、制造及服务，主营产品包括高中电流、高能离子注入系统以及半导体芯片制造用固化系统。
Prestige Consumer Healthcare Inc.是一家美国企业，主营非处方健康护理产品及家用清洁产品的营销与分销业务。该公司于1996年由Medtech Products、Prestige Brands International及Spic and Span三家公司合并成立，总部位于纽约州塔里敦，在弗吉尼亚州林奇堡设有生产工厂。
ACLS vs PBH — 直观对比
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $238.3M | $283.4M |
| 净利润 | $34.3M | $46.7M |
| 毛利率 | 47.0% | 55.5% |
| 营业利润率 | 15.2% | 29.1% |
| 净利率 | 14.4% | 16.5% |
| 营收同比 | -5.6% | -2.4% |
| 净利润同比 | -31.3% | -23.5% |
| 每股收益（稀释后） | $1.11 | $0.97 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $238.3M | $283.4M | ||
| Q3 25 | $213.6M | $274.1M | ||
| Q2 25 | $194.5M | $249.5M | ||
| Q1 25 | $192.6M | $296.5M | ||
| Q4 24 | $252.4M | $290.3M | ||
| Q3 24 | $256.6M | $283.8M | ||
| Q2 24 | $256.5M | $267.1M | ||
| Q1 24 | $252.4M | $277.0M |
| Q4 25 | $34.3M | $46.7M | ||
| Q3 25 | $26.0M | $42.2M | ||
| Q2 25 | $31.4M | $47.5M | ||
| Q1 25 | $28.6M | $50.1M | ||
| Q4 24 | $50.0M | $61.0M | ||
| Q3 24 | $48.6M | $54.4M | ||
| Q2 24 | $50.9M | $49.1M | ||
| Q1 24 | $51.6M | $49.5M |
| Q4 25 | 47.0% | 55.5% | ||
| Q3 25 | 41.6% | 55.3% | ||
| Q2 25 | 44.9% | 56.2% | ||
| Q1 25 | 46.1% | 57.3% | ||
| Q4 24 | 46.0% | 55.5% | ||
| Q3 24 | 42.9% | 55.5% | ||
| Q2 24 | 43.8% | 54.7% | ||
| Q1 24 | 46.0% | 54.8% |
| Q4 25 | 15.2% | 29.1% | ||
| Q3 25 | 11.7% | 29.1% | ||
| Q2 25 | 14.9% | 28.8% | ||
| Q1 25 | 15.1% | 29.8% | ||
| Q4 24 | 21.6% | 31.7% | ||
| Q3 24 | 18.3% | 29.7% | ||
| Q2 24 | 20.6% | 27.0% | ||
| Q1 24 | 22.4% | 29.7% |
| Q4 25 | 14.4% | 16.5% | ||
| Q3 25 | 12.2% | 15.4% | ||
| Q2 25 | 16.1% | 19.0% | ||
| Q1 25 | 14.8% | 16.9% | ||
| Q4 24 | 19.8% | 21.0% | ||
| Q3 24 | 18.9% | 19.2% | ||
| Q2 24 | 19.8% | 18.4% | ||
| Q1 24 | 20.4% | 17.9% |
| Q4 25 | $1.11 | $0.97 | ||
| Q3 25 | $0.83 | $0.86 | ||
| Q2 25 | $0.98 | $0.95 | ||
| Q1 25 | $0.88 | $1.00 | ||
| Q4 24 | $1.54 | $1.22 | ||
| Q3 24 | $1.49 | $1.09 | ||
| Q2 24 | $1.55 | $0.98 | ||
| Q1 24 | $1.57 | $0.98 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $374.3M | $62.4M |
| 总债务越低越好 | — | $1.0B |
| 股东权益账面价值 | $1.0B | $1.8B |
| 总资产 | $1.4B | $3.5B |
| 负债/权益比越低杠杆越低 | — | 0.56× |
8季度趋势，按日历期对齐
| Q4 25 | $374.3M | $62.4M | ||
| Q3 25 | $449.6M | $119.1M | ||
| Q2 25 | $549.8M | $139.5M | ||
| Q1 25 | $587.1M | $97.9M | ||
| Q4 24 | $571.3M | $50.9M | ||
| Q3 24 | $579.4M | $51.5M | ||
| Q2 24 | $548.3M | $34.3M | ||
| Q1 24 | $530.2M | $46.5M |
| Q4 25 | — | $1.0B | ||
| Q3 25 | — | $993.1M | ||
| Q2 25 | — | $992.7M | ||
| Q1 25 | — | $992.4M | ||
| Q4 24 | — | $992.0M | ||
| Q3 24 | — | $1.1B | ||
| Q2 24 | — | $1.1B | ||
| Q1 24 | — | $1.1B |
| Q4 25 | $1.0B | $1.8B | ||
| Q3 25 | $1.0B | $1.8B | ||
| Q2 25 | $1.0B | $1.9B | ||
| Q1 25 | $1.0B | $1.8B | ||
| Q4 24 | $1.0B | $1.8B | ||
| Q3 24 | $975.6M | $1.7B | ||
| Q2 24 | $934.9M | $1.7B | ||
| Q1 24 | $901.7M | $1.7B |
| Q4 25 | $1.4B | $3.5B | ||
| Q3 25 | $1.4B | $3.4B | ||
| Q2 25 | $1.3B | $3.4B | ||
| Q1 25 | $1.3B | $3.4B | ||
| Q4 24 | $1.3B | $3.3B | ||
| Q3 24 | $1.3B | $3.3B | ||
| Q2 24 | $1.3B | $3.3B | ||
| Q1 24 | $1.3B | $3.3B |
| Q4 25 | — | 0.56× | ||
| Q3 25 | — | 0.54× | ||
| Q2 25 | — | 0.54× | ||
| Q1 25 | — | 0.54× | ||
| Q4 24 | — | 0.55× | ||
| Q3 24 | — | 0.61× | ||
| Q2 24 | — | 0.65× | ||
| Q1 24 | — | 0.68× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-6.6M | $78.3M |
| 自由现金流经营现金流 - 资本支出 | $-8.9M | $75.3M |
| 自由现金流率自由现金流/营收 | -3.7% | 26.6% |
| 资本支出强度资本支出/营收 | 1.0% | 1.1% |
| 现金转化率经营现金流/净利润 | -0.19× | 1.68× |
| 过去12个月自由现金流最近4个季度 | $107.0M | $267.2M |
8季度趋势，按日历期对齐
| Q4 25 | $-6.6M | $78.3M | ||
| Q3 25 | $45.4M | $57.5M | ||
| Q2 25 | $39.7M | $79.0M | ||
| Q1 25 | $39.8M | $61.8M | ||
| Q4 24 | $12.8M | $65.1M | ||
| Q3 24 | $45.7M | $69.8M | ||
| Q2 24 | $40.1M | $54.8M | ||
| Q1 24 | $42.2M | $66.9M |
| Q4 25 | $-8.9M | $75.3M | ||
| Q3 25 | $43.3M | $55.4M | ||
| Q2 25 | $37.7M | $78.2M | ||
| Q1 25 | $34.8M | $58.4M | ||
| Q4 24 | $8.1M | $63.5M | ||
| Q3 24 | $41.8M | $67.8M | ||
| Q2 24 | $38.1M | $53.6M | ||
| Q1 24 | $40.6M | $63.8M |
| Q4 25 | -3.7% | 26.6% | ||
| Q3 25 | 20.3% | 20.2% | ||
| Q2 25 | 19.4% | 31.3% | ||
| Q1 25 | 18.1% | 19.7% | ||
| Q4 24 | 3.2% | 21.9% | ||
| Q3 24 | 16.3% | 23.9% | ||
| Q2 24 | 14.8% | 20.1% | ||
| Q1 24 | 16.1% | 23.0% |
| Q4 25 | 1.0% | 1.1% | ||
| Q3 25 | 0.9% | 0.8% | ||
| Q2 25 | 1.0% | 0.3% | ||
| Q1 25 | 2.6% | 1.2% | ||
| Q4 24 | 1.8% | 0.5% | ||
| Q3 24 | 1.5% | 0.7% | ||
| Q2 24 | 0.8% | 0.4% | ||
| Q1 24 | 0.6% | 1.1% |
| Q4 25 | -0.19× | 1.68× | ||
| Q3 25 | 1.75× | 1.36× | ||
| Q2 25 | 1.27× | 1.66× | ||
| Q1 25 | 1.39× | 1.23× | ||
| Q4 24 | 0.26× | 1.07× | ||
| Q3 24 | 0.94× | 1.28× | ||
| Q2 24 | 0.79× | 1.12× | ||
| Q1 24 | 0.82× | 1.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACLS
| Products | $224.6M | 94% |
| Services | $13.7M | 6% |
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
